桑白皮生物碱与辛伐他汀联用对高脂血症大鼠作用研究

doi:10.12092/j.issn.1009-2501.2020.03.006

中国临床药理学与治疗学 ›› 2020, Vol. 25 ›› Issue (3): 278-284.doi: 10.12092/j.issn.1009-2501.2020.03.006

桑白皮生物碱与辛伐他汀联用对高脂血症大鼠作用研究

李佳丹¹, 鲁琛²

¹杭州市第一人民医院，杭州 310000，浙江；²浙江大学附属第二医院，杭州 310009，浙江

收稿日期:2018-07-04 修回日期:2019-01-16 出版日期:2020-03-26 发布日期:2020-04-13
通讯作者: 鲁琛，女，本科，主管护师，研究方向：门诊护理研究。 Tel:13588159082 E-mail： 2503090@zju.edu.cn
作者简介:李佳丹，女，本科，药师，研究方向：药学。 Tel:13456879234 E-mail：alice515@126.com
基金资助:
浙江省基础公益研究项目(LY18H170003)，浙江省医药卫生科技计划(2015KYA105)

Synergistic effects of Cortex Mori alkaloids combined with Simvastatin in rats with hyperlipidaemia

LI Jiadan¹，LU Chen²

¹Hangzhou First People's Hospital，Hangzhou 310000，Zhejiang，China；² The Second Affiliate Hospital of Zhejiang University, Hangzhou 310009, Zhejiang，China

Received:2018-07-04 Revised:2019-01-16 Online:2020-03-26 Published:2020-04-13

摘要/Abstract

摘要： 目的:探讨桑白皮生物碱与辛伐他汀联用对高脂血症金黄地鼠的降脂作用。方法:以高脂饲料喂养金黄地鼠6周建立高脂血症模型，将40只金黄地鼠随机分为正常组、模型组、桑白皮生物碱组(25 mg·kg-1·d-1)，辛伐他汀组(15 mg·kg-1·d-1)和联合用药组(桑白皮生物碱25 mg·kg-1·d-1，辛伐他汀15 mg·kg-1·d-1)，灌胃给药2周后心脏采血测定TG、TC、LDL-C、HDL-C等血生化指标以及ALT、AST、CRP、NO、Lp-PLA2水平；肝脏HE染色观察病理改变，油红O染色观察肝细胞脂质沉积情况。结果:与模型组相比，联合用药组的TC水平明显降低 (P<0.05)；辛伐他汀组和联合用药组的LDL-C水平明显降低（P<0.05）；联合用药组NO水平呈明显升高（P<0.05），且与桑白皮生物碱组和辛伐他汀组相比差异均具有统计学意义；桑白皮生物碱组、辛伐他汀组以及联合用药组均能够明显降低CRP的水平（P<0.05）；联合用药能够明显降低Lp-PLA2的水平（P<0.05）。肝脏HE染色和油红O染色结果显示药物治疗后均能够改善肝脏的病变情况和脂质沉积，且联合用药组的改善情况要优于单独使用二者（P<0.05）。结论:辛伐他汀联合桑白皮生物碱给药治疗对于改善高脂血症金黄地鼠的脂质水平和炎症程度更为有效，桑白皮生物碱可以作为辛伐他汀的辅助用药，有望为临床上治疗高脂血症提供新的选择。

关键词: 高血脂, 辛伐他汀, 桑白皮生物碱, 炎症, 内皮功能障碍

Abstract: AIM: To explore the lipid lowering effect of Cortex Mori alkaloids combined with simvastatin on hyperlipidemia rats. METHODS: Hyperlipidemia model was established by feeding golden hamsters with high-fat diet for 6 weeks, and 40 golden hamsters were randomly divided into normal group, model group, Cortex Mori alkaloids group (CMA, 25 mg·kg-1·d-1),simvastatin group (15 mg·kg-1·d-1) and combination group (Cortex Mori alkaloids, 25 mg·kg-1·d-1, simvastatin 15 mg·kg-1·d-1). 2 weeks after the intragastric administration, cardiac blood sampling was used to determine the blood biochemical indexes such as TG，TC，LDL-C，HDL-C, as well as the levels of ALT，AST，CRP， NO，Lp-PLA2.Liver HE staining was used to observe pathological changes, and liver cell lipid deposition was observed by oil red O staining. RESULTS:Compared with the model group, TC levels in combination group were significantly reduced (P<0.05), LDL-C levels in simvastatin group and the combination group were significantly reduced (P<0.05).The level of NO in the combined group was significantly increased (P<0.05), and the difference was statistically significant compared with that in Cortex Mori alkaloids group and simvastatin group (P<0.05) .The levels of CRP were significantly decreased in Cortex Mori alkaloids group, simvastatin group and the combination group (P<0.05).The level of Lp-PLA2 in combination group was significantly reduced (P<0.05). The results of liver HE staining and oil red O staining showed that both of them could improve the hepatic lesion and lipid deposition after drug treatment, and the improvement of the combination group was better than that of the two groups alone. CONCLUSION: Simvastatin combined with Cortex Mori alkaloids can effectively decrease lipid level and inflammatory level of golden hamstrel with hyperlipidemia.Cortex Mori alkaloids can be used as the auxiliary drug of simvastatin, which is expected to provide a new choice for clinical treatment of hyperlipidemia.

Key words: hyperlipidemia, simvastatin, Cortex Mori alkaloids, inflammation, endothelial dysfunction

中图分类号:

李佳丹，鲁琛. 桑白皮生物碱与辛伐他汀联用对高脂血症大鼠作用研究[J]. 中国临床药理学与治疗学, 2020, 25(3): 278-284.

LI Jiadan，LU Chen. Synergistic effects of Cortex Mori alkaloids combined with Simvastatin in rats with hyperlipidaemia[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(3): 278-284.

参考文献

［1］Yan L, Xu MT, Yuan L, et al. Prevalence of dyslipidemia and its control in type 2 diabetes: A multicenter study in endocrinology clinics of China［J］. J Clin Lipidol, 2016, 10(1):150-160.
［2］Xu DH,Wang F,Yan W.Comparison of commonly used statins［J］.Chin J Mod Appl Pharm，2018,35(7):1112-1117.
［3］Al Mamun A, Hashimoto M, Katakura M, et al.Effect of dietary n-3 fatty acids supplementation on fatty acid metabolism in atorvastatin-administered SHR.Cg-Lepr/NDmcr rats, a metabolic syndrome model［J］. Biomed Pharmacother, 2017,85:372-379.
［4］谢珍, 康桦, 何立成,等.深海鱼油对高脂血症模型大鼠血脂的影响及机制探讨［J］.中国临床药理学与治疗学, 2017, 22(8):870-874.
［5］Zheng D, Cai A, Xu R, et al. Effects and potential mechanism of atorvastatin treatment on Lp-PLA2 in rats with dyslipidemia［J］. Arch Med Sci,2018, 14(3):629-634.
［6］张静, 高英, 罗娇艳,等.桑白皮不同部位对实验性高脂糖尿病小鼠的影响［J］.中药新药与临床药理, 2014, 25(2):159-164.
［7］Shafik NM, Baalash A, Ebeid AM.Synergistic cardioprotective effects of combined chromium picolinate and atorvastatin treatment in triton X-100-induced hyperlipidemia in rats: impact on some biochemical markers［J］. Biol Trace Elem Res,2017, 180(2):255-264.
［8］Owens AP, Byrnes JR, Mackman N.Hyperlipidemia, tissue factor, coagulation, and simvastatin. Trends in cardiovascular medicine［J］. Trends Cardiovasc Med,2014, 24(3):95-98.
［9］Ahmed M, El Bakly WM, Zaki AM, et al. Bupropion effects on high-fat diet-induced steatohepatitis and endothelial dysfunction in rats: role of tumour necrosis factor-alpha LID［J］. J Pharm Pharmacol,2014, 66(6) :793-801.
［10］Maqbool M, Cooper ME，Kam JD. Cardiovascular disease and diabetic kidney disease［J］. Saudi J Biol Sci, 2018, 38(3):217-232.
［11］姜海, 姜国志, 陈钟,等. 姜黄提取物联合阿托伐他汀钙对高脂血症小鼠降血脂作用的研究［J］.中国临床药理学与治疗学, 2017, 22(1):48-51.
［12］Sever PS, Poulter NR, Chang CL, et al. Evaluation of C-Reactive Protein before and bn-treatment as a predictorof benefit of atorvastatin［J］. J Am Coll Cardiol,2013, 62(8):717-729.
［13］Tellis CC, Tselepis AD. Pathophysiological role and clinical significance of lipoprotein-associated phospholipase A (Lp-PLA) bound to LDL and HDL［J］. Curr Pharm Des,2014, 20(40):6256-6269.
［14］Guo R, Nair S, Zhang Y, et al. Adiponectin deficiency rescues high-fat diet-induced hepatic injury, apoptosis and autophagy loss despite persistent steatosis［J］.Int J Obes, 2017, 41 (9) :1403-1412.
［15］解冰川, 李艳敏, 王彦永,等. MMP-9及hs-CRP与动脉粥样硬化、脑卒中关系的研究进展［J］. 临床误诊误治, 2013, 26(5):97-100.
［16］Younus A, Humayun C, Ahmad R, et al. Lipoprotein-associated phospholipase A2 and its relationship with markers of subclinical cardiovascular disease: A systematic review［J］. J Clin Lipidol,2017,11(2):328-337.
［17］Ikonomidis I, Kadoglou NNP, Tritakis V, et al. Association of Lp-PLA2 with digital reactive hyperemia, coronary flow reserve, carotid atherosclerosis and arterial stiffness in coronary artery disease［J］. Atherosclerosis, 2014, 23 (1):34-41.
［18］Chae JS, Kwak JH, Kim M, et al. Effects of A379V variant of the Lp-PLA2 gene on Lp-PLA2 activity and markers of oxidative stress and endothelial function in Koreans［J］. J Thromb，Thrombolysis, 2014, 38(4):477-484.

[1]	廖梦玲, 汪艳, 罗静, 王诺妍, 华玲, 张瑜, 邓非, 袁月, 周军, 周红. 青蒿琥酯抑制巨噬细胞释放前炎症细胞因子的分子作用机制研究[J]. 中国临床药理学与治疗学, 2023, 28(9): 969-978.
[2]	王鑫昱, 陈亦鹏, 马永力, 何君妃. “杜仲-当归”调控NLPR3炎症小体对骨关节炎大鼠改善作用的研究[J]. 中国临床药理学与治疗学, 2023, 28(7): 751-757.
[3]	李雅亭, 岳红梅, 刘苗苗, 许金回, 武兴东, 朱浩斌. 磷酸二酯酶4抑制剂作为特发性肺纤维化药物治疗的可能性[J]. 中国临床药理学与治疗学, 2023, 28(7): 818-823.
[4]	赵灵芝, 何艳君, 谢建琴, 尤崇革. rhsTM对动脉粥样硬化的治疗作用机制研究进展[J]. 中国临床药理学与治疗学, 2023, 28(7): 832-840.
[5]	李阳, 潘维忠, 张晓录, 于翠翠. 回收式自体血回输对行剖宫产术患者免疫功能及炎症反应的影响[J]. 中国临床药理学与治疗学, 2023, 28(5): 514-524.
[6]	侯瑞英, 郭莉阁, 焦伟杰, 杜蕾, 吴桂月, 赵旭. 消渴舒方对2型糖尿病模型大鼠血清炎症因子的影响及其机制研究[J]. 中国临床药理学与治疗学, 2023, 28(4): 377-382.
[7]	李军民, 牛恒立, 谢明全, 苏金龙. 山楂黄酮抗动脉粥样硬化及降血脂作用机制研究[J]. 中国临床药理学与治疗学, 2023, 28(3): 276-282.
[8]	黄玉荣, 张红强, 游蓉丽, 贾颖, 王艳, 樊杰, 王颖莉. 青黛散外用凝胶对特异性皮炎小鼠的改善作用研究[J]. 中国临床药理学与治疗学, 2023, 28(1): 19-28.
[9]	王欣, 孙合亮, 张庆伟, 刘存明, 王忠云, 杨春. 小剂量艾司氯胺酮在胸腔镜下肺叶切除术患者术后镇痛中的作用[J]. 中国临床药理学与治疗学, 2022, 27(9): 998-1003.
[10]	毛姝英, 金蔚, 付思思, 刘珂安琪, 周志豪, 王广基, 梁艳. 口服脾多肽改善氨水诱导的小鼠咳嗽和体内炎症[J]. 中国临床药理学与治疗学, 2022, 27(6): 601-607.
[11]	金依依, 周科挺, 杨成成, 徐萍, 朱素燕. 蛇床子素抑制NF-κB和p38/MAPK改善糖尿病诱导的肾脏损伤[J]. 中国临床药理学与治疗学, 2022, 27(6): 622-631.
[12]	于泽芳, 范理菊, 尹晓玉, 高丽丽, 董占军. 新型速效抗抑郁药的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(5): 595-600.
[13]	高家荣, 施苗苗, 陈浩, 姜辉, 秦秀娟. 芪藤消浊颗粒介导miR-339-5p对慢性肾小球肾炎大鼠炎症指标的影响[J]. 中国临床药理学与治疗学, 2022, 27(4): 457-465.
[14]	常书福. 冠心病药物治疗进展[J]. 中国临床药理学与治疗学, 2022, 27(4): 405-408.
[15]	王瑞杰, 王亮, 徐丹, 周淼淼, 李纪明. PCSK9抑制剂对冠心病患者血脂及炎症因子的影响[J]. 中国临床药理学与治疗学, 2022, 27(4): 409-417.

桑白皮生物碱与辛伐他汀联用对高脂血症大鼠作用研究

Synergistic effects of Cortex Mori alkaloids combined with Simvastatin in rats with hyperlipidaemia

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价